USANA Health Sciences, Inc. announced its fourth quarter and fiscal year 2023 financial results, posting net sales of $921 million in 2023, down from $999 million in fiscal 2022. Diluted EPS in fiscal 2023 totaled $3.30, compared to $3.59 in fiscal 2022.
Fourth quarter net sales were $221 million, down from $228 million in the fourth quarter of 2022, but up from $213 million in the third quarter of 2023.
Asia Pacific continues to be the strongest region for the company, with net sales of $177 million and 383,000 active customers, followed by Greater China, which saw net sales of $116 million and hosts 255,000 active customers.
“USANA delivered solid fourth quarter operating results, which exceeded our expectations,” said Jim Brown, USANA President and Chief Executive Officer. “Our sales strengthened, in part, in response to a global incentive offering that was particularly effective in our Greater China region where it helped generate double-digit sequential growth in Active Customer counts. This boost helped to offset the seasonal slowdown we typically experience during the final month of the quarter and helped us finish the year strong.”
Guidance for fiscal 2024 now includes net sales between $850 million – $920 million, with an EPS between $2.40-$3.00.
